- Tous > Medicine Access and Rational Use > Rational Use
- Tous > Quality and Safety: Medicines > Quality Assurance
- Tous > Quality and Safety: Medicines > Safety and Efficacy
- Mots-clés > adverse drug reactions monitoring
- Mots-clés > adverse event (AE)
- Mots-clés > anti-tuberculosis medicines
- Mots-clés > assessment of risks - prevention
- Mots-clés > Drug-resistant tuberculosis (DR-TB)
- Mots-clés > efficacy and safety of medicines
- Mots-clés > Extensively drug-resistant tuberculosis (XDR-TB)
- Mots-clés > pharmacovigilance
- Mots-clés > risk assessment and evaluation
- Mots-clés > risk/benefit ratio
(2013; 40 pages)
Systems for Improved Access to Pharmaceuticals and Services. 2013. Development of a Risk-Based Approach and Tools for Improving Safe and Rational Use of Tuberculosis Medicines. Submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program. Arlington, VA: Management Sciences for Health.
More than 20 anti-tuberculosis (TB) medicines are being used today. These medicines are taken in different combinations simultaneously. There is a high probability of having an adverse reaction during therapy with anti-TB medicines because of the lengthy period of use required for a complete cure. The fact that most of these medicines have been in use for decades and clinicians are aware of the associated risk and adverse drug reactions (ADRs) is not a guarantee or assurance of completely safe use, as there are still gaps in the current information for these medicines.